Clinicopathological and immunohistochemical characteristics in male breast cancer: A retrospective case series
Oncologist, ISSN: 1549-490X, Vol: 20, Issue: 6, Page: 586-592
2015
- 63Citations
- 77Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations63
- Citation Indexes63
- 63
- CrossRef39
- Captures77
- Readers77
- 77
Article Description
Back ground. Due to its rarity, male breast cancer (mBC) remains an inadequately characterized disease, and current evidence for treatment derives from female breast cancer (FBC). Methods. We retrospectively analyzed the clinic opathological characteristics, treatment patterns, and outcomes of mBCs treated from 2000 to 2013. Results. From a total of 97 patients with mBC, 6 (6.2%) with ductal in situ carcinoma were excluded, and 91 patients with invasive carcinoma were analyzed. Median age was 65 years (range: 25-87 years). Estrogen receptors were positive in 88 patients (96.7%), and progesterone receptors were positive in 84 patients (92.3%). HER-2 was over expressed in 13 of 85 patients (16%). Median follow-up was 51.5 months (range: 0.5-219.3 months). Five-year progression-free survival (PFS) was 50%, whereas overall survival (OS) was 68.1%. Patients with grades 1 and 2 presented 5-year PFS of 71% versus 22.5% for patients with grade 3 disease; 5-year OS was 85.7% for patients with grades 1 and 2 versus 53.3% of patients with grade 3. Ki-67 score >20% and adjuvant chemotherapy were also statistically significant for OS on univariate analyses. Twenty-six of 87 patients (29.8%) experienced recurrent disease and 16 of 91 patients (17.6%) developed a second neoplasia. Conclusion. Male breast cancer shows different biological patterns compared with FBC, with higher positive hormone-receptor status and lower HER-2 over expression. Grade 3 and Ki-67 >20% were associated with shorter OS.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84932624685&origin=inward; http://dx.doi.org/10.1634/theoncologist.2014-0243; http://www.ncbi.nlm.nih.gov/pubmed/25948676; https://academic.oup.com/oncolo/article/20/6/586/6399694; https://dx.doi.org/10.1634/theoncologist.2014-0243; https://academic.oup.com/oncolo/article-pdf/20/6/586/41871505/oncolo_20_6_586.pdf; http://theoncologist.alphamedpress.org/lookup/doi/10.1634/theoncologist.2014-0243; http://theoncologist.alphamedpress.org/content/20/6/586.abstract; http://theoncologist.alphamedpress.org/content/20/6/586.full; http://theoncologist.alphamedpress.org/content/20/6/586.full.pdf; http://theoncologist.alphamedpress.org/content/20/6/586; https://theoncologist.onlinelibrary.wiley.com/doi/10.1634/theoncologist.2014-0243; https://onlinelibrary.wiley.com/doi/abs/10.1634/theoncologist.2014-0243; https://onlinelibrary.wiley.com/doi/full/10.1634/theoncologist.2014-0243; https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2014-0243; http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theoncologist.2014-0243
Oxford University Press (OUP)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know